Soligenix announces new HyBryte™ trial data for CTCL treatment, with presentations at a 2026 dermatology workshop. Learn about this breakthrough therapy and itsSoligenix announces new HyBryte™ trial data for CTCL treatment, with presentations at a 2026 dermatology workshop. Learn about this breakthrough therapy and its

Soligenix to Present New HyBryte Data for Cutaneous T-Cell Lymphoma Treatment at Dermatology Workshop

2026/03/23 22:27
2 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Soligenix Inc. announced that new supportive trial data for its HyBryte photodynamic therapy in treating cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026. The presentations will occur ahead of the American Academy of Dermatology Annual Meeting and will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor.

The data supports HyBryte’s potential as a therapeutic option for CTCL, a rare cancer of white blood cells that primarily affects the skin. The company’s Specialized BioTherapeutics business segment is developing HyBryte, also known as SGX301 or synthetic hypericin sodium, as a novel photodynamic therapy utilizing safe visible light. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company’s development programs in this business segment also include expansion of synthetic hypericin into psoriasis, and development of dusquetide for treating inflammatory diseases including oral mucositis in head and neck cancer.

The company maintains a newsroom where the latest updates relating to SNGX are available at https://ibn.fm/SNGX. The full press release containing this announcement can be viewed at https://ibn.fm/iTepg. The presentation of this new data represents a significant step toward potential regulatory approval and commercialization of HyBryte for patients with cutaneous T-cell lymphoma who currently have limited treatment options.

Beyond its Specialized BioTherapeutics segment, Soligenix’s Public Health Solutions business segment includes development programs for vaccine candidates including RiVax for ricin toxin, vaccines targeting filoviruses such as Marburg and Ebola, and CiVax for prevention of COVID-19. These programs incorporate the company’s proprietary heat stabilization platform technology known as ThermoVax and have been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Soligenix to Present New HyBryte Data for Cutaneous T-Cell Lymphoma Treatment at Dermatology Workshop.

The post Soligenix to Present New HyBryte Data for Cutaneous T-Cell Lymphoma Treatment at Dermatology Workshop appeared first on citybuzz.

Market Opportunity
Cellframe Logo
Cellframe Price(CELL)
$0,04925
$0,04925$0,04925
+0,48%
USD
Cellframe (CELL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

South Korea’s $657 Million Exit from Tesla Signals a Big Crypto Pivot

South Korea’s $657 Million Exit from Tesla Signals a Big Crypto Pivot

In a dramatic shift in investment patterns, South Korean retail investors withdrew $657 million from Tesla stock in August 2025, representing the largest monthly outflow in more than two years. At the same time, by mid-2025, they had shifted more than $12 billion into U.S.-listed companies tied to cryptocurrency, indicating a deepening preference for digital […]
Share
Tronweekly2025/09/18 14:00
MetaMask to Launch Its Token Sooner Than Expected, Says ConsenSys CEO

MetaMask to Launch Its Token Sooner Than Expected, Says ConsenSys CEO

The post MetaMask to Launch Its Token Sooner Than Expected, Says ConsenSys CEO appeared first on Coinpedia Fintech News MetaMask, the world’s leading Web3 wallet and gateway to decentralized apps, is gearing up to launch its own token. In a recent interview, Consensys CEO and Ethereum co-founder Joe Lubin revealed that a MetaMask token could be launched much earlier than people think, sparking excitement among users and investors who have long been waiting for …
Share
CoinPedia2025/09/19 12:56
How is the xStocks tokenized stock market developing?

How is the xStocks tokenized stock market developing?

Author: Heechang Compiled by: TechFlow xStocks offers a tokenized stock service, allowing investors to trade tokenized versions of popular US stocks like Tesla in real time. While still in its early stages, it’s already showing some interesting signs of growth. Observation 1: Trading is concentrated in Tesla (TSLA) As in many emerging markets, trading activity has quickly concentrated on a handful of stocks. Data shows a high concentration of trading volume in the most well-known and volatile stocks, with Tesla being the most prominent example. This concentration is not surprising: liquidity tends to accumulate in assets that retail investors already favor, and early adopters often use familiar high-beta stocks to test new infrastructure. Observation 2: Liquidity decreases on weekends Data shows that on-chain equity trading volume drops to 30% or less of weekday levels over the weekend. Unlike crypto-native assets, which trade seamlessly around the clock, tokenized stocks still inherit the behavioral inertia of traditional market trading hours. Traders appear less willing to trade when reference markets (such as Nasdaq and the New York Stock Exchange) are closed, likely due to concerns about arbitrage, price gaps, and the inability to hedge positions off-chain. Observation 3: Prices move in line with the Nasdaq Another key signal comes from pricing behavior during the initial launch period. Initially, xStocks tokens traded at a significant premium to their Nasdaq counterparts, reflecting market enthusiasm and potential friction in bridging fiat liquidity. However, these premiums gradually diminished over time. Current trading patterns show that the token price is at the upper limit of Tesla's intraday price range and is highly consistent with the Nasdaq reference price. Arbitrageurs appear to be maintaining this price discipline, but there are still small deviations from the intraday highs, indicating some market inefficiencies that may present opportunities and risks for active traders. New opportunities for Korean stock investors? South Korean investors currently hold over $100 billion in US stocks, with trading volume increasing 17-fold since January 2020. Existing infrastructure for South Korean investors to trade US stocks is limited by high fees, long settlement times, and slow cash-out processes, creating opportunities for tokenized or on-chain mirror stocks. As the infrastructure and platforms supporting on-chain US stock markets continue to improve, a new group of South Korean traders will enter the crypto market, which is undoubtedly a huge opportunity.
Share
PANews2025/09/18 08:00